ArmaGen Technologies Obtains $17,000,000 Series A Funding Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=31581031-edf2-4366-ae6c-fb29dc3e7f79&Preview=1 - Date
12/3/2012 - Company Name
ArmaGen Technologies - Mailing Address
914 Colorado Ave Santa Monica, CA 90401 - Company Description
ArmaGen provides platform technology solutions to the ‘blood-brain barrier’ problem, and can non-invasively target recombinant proteins, therapeutic monoclonal antibodies, and siRNA to the brain. - Website
http://www.armagen.com - Transaction Type
Venture Equity - Transaction Amount
$17,000,000 - Transaction Round
Series A - Proceeds Purposes
The company will use the financing to start clinical trials of its biopharmaceutical candidates. - M&A Terms
- Venture Investor
Shire Pharmaceuticals - Venture Investor
Takeda Ventures - Venture Investor
Mitsui & Co. - Venture Investor
Boehringer Ingelheim Venture Fund
